UNSPSC 51352400: Combination contraceptives and estrogens

This classification denotes combination drugs and preparations that a) prevent or reduce probability of fusion of a spermatozoon with an ovum thus resulting in the formation of a zygote (or fertilization), that process called conception, hence the term contraceptives; and/or b) interact with estrogen receptors (or Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription) in target tissues and which thereby stimulate human female reproductive organs.

Typical combination contraceptive and estrogen constituents are chlordiazepoxide, desogestrel, dienogest, drospirenone, estradiol, estrogens, ethinyl estradiol, ethynodiol, and mestranol.

UNSPSC 51352400 Combination contraceptives and estrogens, a Class code, encompasses state and local procurement of pharmaceutical products including oral contraceptives, hormone replacement therapies, and related combination estrogen formulations supplied through established pharmaceutical distribution channels. The code serves health and human services departments, state employee benefit programs, Medicaid agencies, and cooperative purchasing alliances that manage pharmacy benefit programs for state employees, beneficiaries, and institutional healthcare settings. State health agencies and multistate cooperative purchasing organizations are the primary issuing bodies, with procurement typically structured around competitive RFPs and RFQs focused on pricing, product availability, supply chain compliance, and wholesale distribution relationships.

Recent activity centers on Texas and Minnesota. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program that would establish relationships outside traditional pharmacy benefit managers and wholesalers, with responses due the same day. More substantially, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to supply participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026; awarded vendors must comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, maintain relationships with authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, provide pricing in multiple formats, and carry $5 million commercial general liability and $2 million network security liability. The MMCAP contract term runs two years from July 1, 2026, with optional extensions, and evaluates vendors 75 percent on price competitiveness and 25 percent combined on fixed pricing, administrative compliance, EDI capability, and fee structure acceptance.